Document is current

Article History

Received: 23 September 2024

Accepted: 8 March 2025

First Online: 10 April 2025

Declarations

:

: The study was conducted according to the International Council on Harmonisation guidelines and the Declaration of Helsinki. The trial protocol was approved by independent ethics committees and institutional review boards. Written informed consent was provided by patients ahead of study screening.

: Not applicable.

: AO has served as a consultant and/or on advisory boards and/or undertaken clinical trials for AbbVie, GSK, Janssen, Lilly, Novartis, and Pfizer. EF has received honoraria and research grants from AbbVie, BMS, Galapagos, Lilly, MSD, Novartis, Pfizer, Roche, and Sobi. PS has received honoraria and research grants from AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, and UCB through the University of Crete Special Account for Research. JA has received honoraria from AbbVie, AstraZeneca, Biogen, BMS, Fresenius Kabi, Galapagos, Janssen, Lilly, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Roche-Chugai, Sandoz, and Sanofi; and research grants from BMS, Fresenius Kabi, Galapagos, Novartis (Dreamer), and Pfizer (Passerelle). MR has received honoraria and/or support to participate in academic events from AbbVie, Bayer, Pfizer, and Roche. RN has no conflicts of interest to declare. EMB, TG, ILG, and SS are AbbVie employees and may own AbbVie stock or options. DZ has received speaker fees and/or advisory honoraria from AbbVie, AstraZeneca, GSK, Janssen, Lilly, Novartis, Pfizer, Roche, and Sandoz, and research grants from Pfizer. SA has received speaker fees, research grants, and advisory honoraria from AbbVie, Amgen, AstraZeneca, BMS, Gilead, GSK, Hikma, Janssen, Lilly, Novartis, Organon, Pfizer, Roche, Sandoz, Sanofi, and Takeda.